The Therapeutic Goods
Administration (TGA) said it is
performing intensive monitoring
of the safety and risk profile of
Bexsero, Novartis’ meningococcal B
vaccine, following its introduction
to the Australian market.
While fever occurred after
administration of many vaccines,
the TGA said, it had identified that
Bexsero commonly induced fever
in infants and children, including a
high fever.
The Australian Technical Advisory
Group on Immunisation had
recommended prophylactic use of
paracetamol with Bexsero when
administered to children under two
years old, it said.
The TGA is encouraging the
reporting of any seizures associated
with the use of Bexsero to help
with monitoring.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.